# A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

> **NCT07293351** · PHASE1,PHASE2 · RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 234 (estimated)

## Conditions studied

- Advanced Renal Cell Carcinoma (RCC)

## Interventions

- **DRUG:** Pumitamig
- **DRUG:** Ipilimumab
- **DRUG:** Cabozantinib
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT07293351
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-26
- **Primary completion:** 2029-11-28
- **Final completion:** 2031-11-26
- **Target enrollment:** 234 (ESTIMATED)
- **Last updated:** 2026-05-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07293351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07293351, "A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)". Retrieved via MORVS 2026-10-12 from https://api.morvs.ai/clinical/NCT07293351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*